Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Nanomedicine. 2015 Mar 19;10:2249-59. doi: 10.2147/IJN.S79480. eCollection 2015.

Rescuing compound bioactivity in a secondary cell-based screening by using γ-cyclodextrin as a molecular carrier.

Author information

  • 1Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain ; IIS Aragón, Zaragoza, Spain ; Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit IQFR-CSIC-BIFI, Universidad de Zaragoza, Zaragoza, Spain.
  • 2Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit IQFR-CSIC-BIFI, Universidad de Zaragoza, Zaragoza, Spain.
  • 3Instituto de Nanociencia de Aragon (INA), Universidad de Zaragoza, Zaragoza, Spain.
  • 4Instituto de Nanociencia de Aragon (INA), Universidad de Zaragoza, Zaragoza, Spain ; Instituto de Ciencia de Materiales de Aragón (ICMA), CSIC-Universidad de Zaragoza, Zaragoza, Spain ; Institute NanoBiomedicine and Engineering, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
  • 5IIS Aragón, Zaragoza, Spain ; Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain ; Servicio de Aparato Digestivo, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain ; Department of Medicine, University of Zaragoza, Zaragoza, Spain.
  • 6IIS Aragón, Zaragoza, Spain ; Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit IQFR-CSIC-BIFI, Universidad de Zaragoza, Zaragoza, Spain ; Fundacion ARAID, Government of Aragon, Spain.
  • 7Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain ; IIS Aragón, Zaragoza, Spain ; Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit IQFR-CSIC-BIFI, Universidad de Zaragoza, Zaragoza, Spain ; Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain.

Abstract

In vitro primary screening for identifying bioactive compounds (inhibitors, activators or pharmacological chaperones) against a protein target results in the discovery of lead compounds that must be tested in cell-based efficacy secondary screenings. Very often lead compounds do not succeed because of an apparent low potency in cell assays, despite an excellent performance in primary screening. Primary and secondary screenings differ significantly according to the conditions and challenges the compounds must overcome in order to interact with their intended target. Cellular internalization and intracellular metabolism are some of the difficulties the compounds must confront and different strategies can be envisaged for minimizing that problem. Using a novel screening procedure we have identified 15 compounds inhibiting the hepatitis C NS3 protease in an allosteric fashion. After characterizing biophysically the interaction with the target, some of the compounds were not able to inhibit viral replication in cell assays. In order to overcome this obstacle and potentially improve cellular internalization three of these compounds were complexed with γ-cyclodextrin. Two of them showed a five- and 16-fold activity increase, compared to their activity when delivered as free compounds in solution (while γ-cyclodextrin did not show antiviral activity by itself). The most remarkable result came from a third compound that showed no antiviral activity in cell assays when delivered free in solution, but its γ-cyclodextrin complex exhibited a 50% effective concentration of 5 μM. Thus, the antiviral activity of these compounds can be significantly improved, even completely rescued, using γ-cyclodextrin as carrier molecule.

KEYWORDS:

NS3 protease; antiviral compounds; cyclodextrins; drug activity; drug delivery; hepatitis C; primary and secondary screenings; vehiculization; virus replicon system

PMID:
25834436
PMCID:
PMC4371900
DOI:
10.2147/IJN.S79480
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Support Center